<code id='8C44280497'></code><style id='8C44280497'></style>
    • <acronym id='8C44280497'></acronym>
      <center id='8C44280497'><center id='8C44280497'><tfoot id='8C44280497'></tfoot></center><abbr id='8C44280497'><dir id='8C44280497'><tfoot id='8C44280497'></tfoot><noframes id='8C44280497'>

    • <optgroup id='8C44280497'><strike id='8C44280497'><sup id='8C44280497'></sup></strike><code id='8C44280497'></code></optgroup>
        1. <b id='8C44280497'><label id='8C44280497'><select id='8C44280497'><dt id='8C44280497'><span id='8C44280497'></span></dt></select></label></b><u id='8C44280497'></u>
          <i id='8C44280497'><strike id='8C44280497'><tt id='8C44280497'><pre id='8C44280497'></pre></tt></strike></i>

          entertainment

          entertainment

          author:entertainment    Page View:88834
          Sens. Ron Wyden and Mike Crapo introduced a mental health, PBM reform and substance use policy package. Drew Angerer/Getty Images

          WASHINGTON — A key Senate panel announced it will consider more policies to regulate pharmacy middlemen and ensure patients aren’t paying more than insurers do for medications.

          The package crafted by Senate Finance Chair Ron Wyden (D-Ore.) and Mike Crapo (R-Idaho) is slated to be marked up on Nov. 8, and includes policy on a broad range of health care priorities, including substance abuse and mental health care, and extensions to provider pay. The pharmacy benefit manager regulations build on a separate package of PBM regulations that the panel passed in July.

          advertisement

          The most impactful proposal would allow the Department of Health and Human Services to designate a list of so-called discounted drugs. Medicare beneficiaries taking those drugs would see their share of the cost based on the net price, rather than the list price, under the new proposal.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          In utero gene editing: an explainer
          In utero gene editing: an explainer

          AnnaYeo/STATRecentlyapprovedgenetherapiesofferpatientsone-time,potentiallycurativetreatmentsforgenet

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Ed Silverman on new gene therapies, biosimilars, coffee, and more

          STAT'sEdSilvermanonstageattheSTATBreakthroughSummitin2023.SarahGonzalezforSTATIn2023,STATlaunchedabr